COVID-19 (Coronavirus)

The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent  severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease – 2019 (COVID-19) in facility staff and residents in skilled nursing and assisted living facilities with a high risk of SARS-CoV-2 exposure. Participants with a high risk of SARS-CoV-2 exposure will receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn.

To speak with a study representative, call 718-210-9713.

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2)

The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.

A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. 

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19  

Pediatric COVID-19 (Coronavirus)

The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. 

A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19) (BLAZE-5)  

The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)

The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. 


A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)  

The purpose for this study is to determine if the study drug Baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.

COVID-19 (Coronavirus)

Recruiting

A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)

Search Match Terms:

COVID-19 (Coronavirus)

Enter your postal code
to see sites near you

View Trial

Not the right fit? Sign up to receive updates on new trials.

COVID-19 (Coronavirus)

Recruiting

A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)

Search Match Terms:

COVID-19 (Coronavirus)

Enter your postal codeto see sites near you

View Trial

Not the right fit? Sign up to receive updates on new trials.

Enter your postal code
to see sites near you